Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025Faridpur Medical College JournalOpen Access

“New Horizons in T2DM Management: A Review of Emerging Antidiabetic Medications”

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSumit DasAll India Institute of Medical Sciences RaipurCDChandrima DasBaba Farid University of Health Sciences

Discussion

Loading...

Member takes

Overview

This review examines new antidiabetic medications that improve glycemic control and address comorbidities in T2DM patients, highlighting their implications for treatment.

Key Points

  • Next-generation glucagon-like peptide-1 receptor agonists show promise for glycemic control and weight loss in T2DM.
  • SGLT2 inhibitors provide cardiometabolic and renal benefits, making them valuable in T2DM management.
  • Novel therapies like imeglimin enhance insulin signaling pathways, addressing mitochondrial dysfunction.
  • The review highlights the need for innovative approaches to manage T2DM and its associated complications effectively.

Cite This Study

Das et al. (2025) studied this question.

synapsesocial.com/papers/689a094be6551bb0af8cf4ddhttps://doi.org/10.3329/fmcj.v20i2.83147
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recent Improvements in the Treatment of Type 2 Diabetes Mellitus2024
  2. 2Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives2026
  3. 3Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management2025 · 9 citations
  4. 4New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions2024 · 19 citations
  5. 5Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches2024 · 8 citations